It also decreases the recruitment of TAM, and this effect depends on ADAM17 expression by cancer cells; (iii) the targeting of soluble MCAM decreases CRC tumor development in immunocompetent and immunodeficient mouse models; (iv) MCAM expression is elevated in the angiogenic CMS4 subtype of CRC patients and correlates with angiogenic and lymphangiogenic growth factor expression. Here, MCAM is linked to cancer.